Phase 3 study of OBI-822 in patients with Metastatic Breast Cancer

Trial Profile

Phase 3 study of OBI-822 in patients with Metastatic Breast Cancer

Planning
Phase of Trial: Phase III

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Adagloxad simolenin (Primary)
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors OBI Pharma
  • Most Recent Events

    • 01 Mar 2017 According to Amaran Biotechnology media release, OBI Pharma received formal approval from the China Food and Drug Administration to conduct Phase 3 study.
    • 25 Jan 2017 According to an OBI Pharma media release, this trial could be used in a future Biologics License Application (BLA) submission, subject to future amendment.
    • 24 Feb 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top